A Dark Vector Cognition product

Item 6. EXHIBITS

5K characters. Original on sec.gov ·

Item 6. EXHIBITS

(a) Exhibits

Exhibit NumberDescription
10.1Modification No. 02 to Base Agreement, dated as of August 2, 2022, by and between Regeneron Pharmaceuticals, Inc. (the "Registrant") and Advanced Technology International.
10.2*Modification No. 03 to Project Agreement, dated as of May 21, 2021, by and between the Registrant and Advanced Technology International.
10.3Modification No. 04 to Project Agreement, dated as of July 12, 2021, by and between the Registrant and Advanced Technology International.
10.4*Modification No. 06 to Project Agreement, dated as of July 12, 2022, by and between the Registrant and Advanced Technology International.
10.5*Modification P00001 to Supply Agreement, dated as of March 9, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey.
10.6*Modification P00002 to Supply Agreement, dated as of June 17, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey.
10.7Modification P00003 to Supply Agreement, dated as of July 8, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey.
10.8*Modification P00007 to Supply Agreement, dated as of July 29, 2022, by and between the Registrant and the U.S. Army Contracting Command, New Jersey.
31.1Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
31.2Certification of Principal Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
32Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350.
101Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL"): (i) the Registrant's Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021; (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2022 and 2021; (iii) the Registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2022 and 2021; (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021; and (v) the notes to the Registrant's Condensed Consolidated Financial Statements.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
* Certain confidential portions of this exhibit were omitted in accordance with Item 601(b)(10) of Regulation S-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

REGENERON PHARMACEUTICALS, INC.
Date:November 3, 2022By:/s/ Robert E. Landry
Robert E. Landry
Executive Vice President, Finance and
Chief Financial Officer
(Duly Authorized Officer)

Previous: Item 1A. RISK FACTORS